Scientific deep-dive

Retatrutide vs Foundayo (orforglipron) — TRIUMPH-1 vs ATTAIN-1 cross-trial evidence

Retatrutide −25.0% TBWL at 12 mg / 80 wk (TRIUMPH-1, NEJM 2026) vs Foundayo (orforglipron) ~−11% at 17.2 mg / 72 wk (ATTAIN-1), roughly 2.2× on a cross-trial basis. Both are Eli Lilly molecules; Foundayo is FDA-approved (April 2026), retatrutide is investigational.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
12 min read·12 citations

This cross-trial comparison lives in Weight Loss Rankings' living editorial database — 1,180+ research articles and 640+ clinically-verified GLP-1 telehealth providers, sourced only from primary FDA labels, ClinicalTrials.gov registrations, and peer-reviewed PubMed literature.

The honest answer: Foundayo (orforglipron) is FDA-approved for chronic weight management (April 1, 2026 — the first small-molecule (non-peptide) oral GLP-1 approved for obesity) and retatrutide is still investigational. Both are Eli Lilly molecules but use different mechanisms: retatrutide is an injectable triple GIP/GLP-1/glucagon agonist; Foundayo is a daily small-molecule GLP-1 pill. Cross-trial, retatrutide produced roughly 2.2× the mean TBWL of Foundayo (−25.0% at 12 mg in the published TRIUMPH-1 trial vs ~−11% in ATTAIN-1).[11][2]

At a glance

  • Approval: Foundayo is FDA-approved (April 1, 2026); retatrutide is investigational and not FDA-approved; TRIUMPH-1 was published in NEJM in September 2026, and Lilly plans to submit a Biologics License Application in Q1 2027.[11][12]
  • Route: Foundayo is a once-daily oral tablet; retatrutide is a once-weekly subcutaneous injection.[9][3]
  • Mechanism: Foundayo activates GLP-1 only (single receptor); retatrutide activates GIP + GLP-1 + glucagon receptors (triple agonist).[1][2]
  • Weight loss (cross-trial): TRIUMPH-1 retatrutide 12 mg −25.0% mean TBWL at 80 weeks (published NEJM result, treatment-regimen estimand) vs ATTAIN-1 Foundayo 17.2 mg ~−11% mean TBWL at 72 weeks — roughly a 2.2× multiplier in favor of retatrutide.[11][2]
  • GI burden: Both classes have substantial GI adverse events; orforglipron's oral small-molecule kinetics produce a slightly different titration curve than injectable peptides, but discontinuation rates are broadly comparable to other monoagonist GLP-1s.[2]
  • Manufacturer: Both are Eli Lilly. This is a within-portfolio decision, not a brand-vs-brand-competitor comparison.
  • Cross-trial caveat: No head-to-head trial exists. TRIUMPH-1 and ATTAIN-1 differ in duration, baseline population, and dose ladders. The 2.2× multiplier is the best available approximation, not a randomized comparison.

Approval status — Foundayo FDA-approved April 2026, retatrutide investigational

Foundayo (orforglipron) became the first small-molecule (non-peptide) oral GLP-1 FDA-approved for chronic weight management on April 1, 2026. The label covers adults with obesity and adults with overweight plus at least one weight-related comorbidity (the label itself gives no BMI numbers), with a four-step dose ladder (3 / 6 / 12 / 17.2 mg once daily) and 30-day minimum intervals between increases. Section 14 of the prescribing information reports the 17.2 mg labeled-dose efficacy in the ATTAIN-1 population without type 2 diabetes.[9]

Retatrutide is not FDA-approved. The TRIUMPH-1 pivotal Phase 3 trial (NCT05929066) was published in the New England Journal of Medicine in September 2026: −25.0% mean TBWL at the 12 mg dose over 80 weeks on the treatment-regimen estimand, vs −3.9% with placebo.[11][8] Lilly's May 2026 press release had reported a higher −28.3% for the same arm, but that figure used the efficacy estimand (participants who stayed on treatment).[3] TRIUMPH-2, in adults with obesity and type 2 diabetes, was published in The Lancet (2026; PMID 42810372), and its diabetes results are set against Ozempic’s SUSTAIN-7 data in retatrutide vs Ozempic for type 2 diabetes. Lilly plans to submit a Biologics License Application to the FDA in Q1 2027; approval timing will depend on FDA review.[12]

Practical implication for a 2026 patient: only Foundayo can be prescribed and filled today. Retatrutide remains a clinical-trial-only molecule. Any "compounded retatrutide" marketed in 2026 is not produced under the FDCA 503A framework — retatrutide is not on the FDA bulk substance list, has no USP monograph, and is not a discontinued FDA-approved drug. See our retatrutide vs tirzepatide head-to-head for the full regulatory walk-through.

Mechanism — injectable triple agonist vs oral small-molecule GLP-1 RA

Foundayo is a small-molecule non-peptide compound that binds the GLP-1 receptor only. Because it is a small molecule rather than a peptide, it can be formulated as an oral tablet absorbed through the GI tract without the strict empty-stomach plus 4-ounce water requirements of Rybelsus (oral semaglutide). Foundayo can be taken at any time of day, with or without food. It activates a single receptor — the same GLP-1R target that Wegovy, Saxenda, and Rybelsus hit.[2][9]

Retatrutide is a synthetic peptide that activates three receptors simultaneously: GIP, GLP-1, and glucagon. The glucagon-receptor component is what makes retatrutide categorically different from every FDA-approved obesity drug. Glucagon receptor activation increases hepatic energy expenditure, promotes lipolysis, and reduces hepatic steatosis — mechanisms that single-receptor GLP-1 agonists like Foundayo cannot access.[1][7]

The mechanism asymmetry is also the magnitude asymmetry. Triple receptor activation drives larger weight loss but also amplifies the adverse-event signal — particularly a dysesthesia signal in TRIUMPH-1 (12.5% on 12 mg) far more frequent than in Foundayo's trials (1% at 17.2 mg).[3][9]

Weight loss cross-trial — ~2.2× multiplier in favor of retatrutide

The cleanest mean-effect numbers from each pivotal Phase 3 are:

  • Retatrutide 12 mg / 80 weeks (TRIUMPH-1): −25.0% mean total body weight loss on the treatment-regimen estimand in the published NEJM report (−23.7% at 9 mg, −17.6% at 4 mg, −3.9% placebo).[11] Lilly's press release reported −28.3% at 12 mg on the efficacy estimand, and approximately −30.3% at 104 weeks in a BMI ≥ 35 extension cohort (press release only; efficacy estimand).[3]
  • Foundayo 17.2 mg / 72 weeks (ATTAIN-1): approximately −11% mean TBWL at the FDA-approved labeled max dose in adults with obesity without type 2 diabetes (Section 14 of the US Prescribing Information).[2][9]

Dividing the two gives a roughly 2.2× cross-trial multiplier in favor of retatrutide. As an absolute pp number, the gap is roughly 14 percentage points of TBWL at maximum tested dose. The ≥30% TBWL response rate also separates sharply: Lilly's press release (efficacy estimand) reported that roughly 45% of TRIUMPH-1 retatrutide 12 mg participants reached that threshold, while ATTAIN-1 Foundayo 17.2 mg places far fewer patients in the ≥30% bucket.[3][2]

Cross-trial caveat. TRIUMPH-1 and ATTAIN-1 are not a randomized head-to-head. They differ in duration (80 vs 72 weeks), dose ladder, baseline BMI distribution, and the secular context of trial conduct. They are also different molecules — peptide vs small molecule — administered by different routes. The 2.2× number is the best approximation from published data, not a head-to-head finding. A prescriber making an individual decision should treat this magnitude gap as directional rather than precise.

Magnitude comparison

Retatrutide vs Foundayo cross-trial pivotal Phase 3 mean weight loss. TRIUMPH-1 retatrutide 12 mg / 80 wk vs ATTAIN-1 Foundayo 17.2 mg / 72 wk. Indirect comparison — no head-to-head trial. The 104-week extension bar is a Lilly press-release efficacy-estimand figure, not a published result.[2][11][3]

  • Retatrutide 12 mg — TRIUMPH-1 mean TBWL (80 wk, NEJM)25.0 % TBWL
    ~2.2× the Foundayo magnitude cross-trial
  • Foundayo 17.2 mg — ATTAIN-1 mean TBWL (72 wk)11.1 % TBWL
  • Retatrutide 12 mg — TRIUMPH-1 BMI≥35 extension (104 wk, Lilly press release)30.3 % TBWL
    Bariatric-surgery range
  • Foundayo 6 mg — ATTAIN-1 low-dose arm7.5 % TBWL
Retatrutide vs Foundayo cross-trial pivotal Phase 3 mean weight loss. TRIUMPH-1 retatrutide 12 mg / 80 wk vs ATTAIN-1 Foundayo 17.2 mg / 72 wk. Indirect comparison — no head-to-head trial. The 104-week extension bar is a Lilly press-release efficacy-estimand figure, not a published result.

Route + frequency — weekly injection vs daily oral pill

Foundayo is a once-daily tablet. It is a small molecule, not a peptide — so it survives gastric digestion and is absorbed via the GI tract without the strict empty-stomach window that Rybelsus requires. Patients take one pill at the same time each day, with or without food.[9]

Retatrutide in the TRIUMPH program is a once-weekly subcutaneous injection administered into the abdomen, thigh, or upper arm via a prefilled pen device, with a multi-month dose-escalation ladder. Refrigerated storage is required for the unopened product (consistent with the rest of the GLP-1 injectable class).[1]

For needle-averse patients, this is the decisive practical difference. Roughly 30-40% of adults report needle anxiety sufficient to delay or refuse injectable medication. Foundayo is the first FDA-approved oral path to clinically meaningful weight loss in this population. The trade-off is that retatrutide's published pivotal mean TBWL is roughly 2.2× Foundayo's — patients who would never start an injectable at all may still achieve clinically meaningful weight loss on a daily pill they will actually take.

Side-effect profile cross-trial

Both classes have substantial gastrointestinal AEs. The exact rates and kinetics differ:

  • Foundayo 17.2 mg / ATTAIN-1: nausea, diarrhea, constipation, vomiting, and dyspepsia dominate. Treatment-emergent AE discontinuations ran roughly 5.3-10.3% in ATTAIN-1 at the labeled-max dose — broadly comparable to STEP-1 Wegovy (~7%) and SURMOUNT-1 Zepbound (4.3-7.1%). GI events were mostly mild to moderate and concentrated during the titration window. See our Foundayo side effects comprehensive review for the full AE table.[2]
  • Retatrutide 12 mg / TRIUMPH-1: nausea 42.4% (vs 14.8% on placebo), diarrhea 32.0% (vs 13.5%), constipation 26.1% (vs 10.9%) and vomiting 25.3% (vs 4.8%), per Lilly's May 21, 2026 topline release. AE discontinuation ran ~11.3% on the 12 mg dose. A categorically different finding is dysesthesia (altered or unpleasant skin sensation) at roughly 12.5% on 12 mg (vs 0.9% placebo), far above the 1% (vs 0.1% placebo) the Foundayo label reports at 17.2 mg.[3][9]

Oral small-molecule GLP-1 kinetics also differ from injectable peptides — Foundayo's daily dosing produces a more consistent receptor-occupancy profile than weekly-pulse injectable peptides, and some prescribers report that titration nausea is qualitatively different (smaller peaks, longer baseline). This has not been quantified in a head-to-head trial; it is a clinical observation reported across the ATTAIN program.

The Foundayo label carries the standard GLP-1 class warnings: boxed warning for thyroid C-cell tumor risk, pancreatitis, gallbladder disease, acute kidney injury, and hypersensitivity. Like every current GLP-1 label, it does not list pregnancy as a contraindication; it warns the drug may cause fetal harm and directs discontinuation once a pregnancy is recognized. Retatrutide is investigational and has no FDA label yet. Foundayo also carries a specific 9 mg dose cap with strong CYP3A4 inhibitors (Section 7 of the US Prescribing Information) — a small molecule's metabolic profile creates drug-drug interactions that the peptide GLP-1 class does not have.[9]

When the oral pill makes more sense

Foundayo is the right choice when:

  • Needle aversion is the gating barrier. A patient who would refuse an injectable will achieve more weight loss on a daily pill than on no medication.
  • BMI 27-35 seeking 8-12% TBWL. The ATTAIN-1 mean is well-matched to this magnitude target; the cost of retatrutide's stronger effect is not warranted when the goal sits inside Foundayo's delivered range.
  • Travel-heavy lifestyle with refrigeration constraints. Foundayo is room-temperature stable and a single pill — substantially simpler than weekly injectable logistics.
  • You can fill the prescription this month. Retatrutide is not FDA-approved and is not legally available outside of clinical-trial enrollment. For the 2026 patient, Foundayo can be prescribed today, alongside other FDA-approved GLP-1 receptor agonists.

Honest tradeoff: lower mean efficacy. A roughly 14 percentage-point gap in mean TBWL is meaningful for high-BMI patients targeting bariatric-range outcomes. For those patients, the right comparison is Foundayo vs an injectable like Zepbound or Wegovy today — and retatrutide later, if FDA approval lands. As a preview of that later choice, retatrutide’s cross-trial results against Wegovy show roughly 1.7 times the weight loss, with no head-to-head trial yet.

When the triple-class injectable makes more sense

Retatrutide will be the right choice (post-approval) when:

  • BMI ≥ 40 and the target is bariatric-range outcomes. The ≥30% TBWL response rate on retatrutide 12 mg approaches sleeve gastrectomy magnitudes — territory no oral GLP-1 monoagonist reaches.
  • Failed an oral GLP-1 RA on efficacy. A patient who completed the ATTAIN-style titration and reached a plateau at 8-10% TBWL while still needing 20-25% to clear comorbidity thresholds is the canonical retatrutide candidate.
  • Comfortable with weekly injection logistics. Patients already injecting Zepbound or Wegovy successfully have functionally cleared this barrier.
  • No active dysesthesia history or peripheral neuropathy. The ~12.5% retatrutide dysesthesia signal is the cleanest specific contraindication in the comparative dataset.

The honest framing for 2026: retatrutide is not yet a choice. For high-BMI patients today, the practical comparison is Foundayo vs Zepbound, with retatrutide as a future option once approval lands.

Cost + availability

Foundayo is available through standard retail pharmacies, LillyDirect, and the Foundayo Self Pay Pharmacy portal. Eli Lilly launched a direct-pay self-pay pricing structure analogous to the Zepbound LillyDirect vial program, but because Foundayo is a tablet, the self-pay logistics are simpler — no cold chain, no pen device manufacturing constraints, no dose-specific supply allocations.[10]

Retatrutide is not commercially available. There is no list price, no PBM formulary placement, no insurance prior authorization pathway, and no self-pay portal. The only legal access route in 2026 is enrollment in an active retatrutide clinical trial. For the pricing mechanisms that will eventually apply once retatrutide is approved, see our retatrutide cost mechanism review.

Eli Lilly's pipeline rationale for both molecules

Both retatrutide and Foundayo are Eli Lilly assets — this is a within-portfolio decision, not a brand-vs-competitor framing. Lilly's strategy spans three monoagonist GLP-1 paths (Trulicity injectable, Foundayo oral, Mounjaro/Zepbound dual agonist) plus the retatrutide triple-class program. Each molecule targets a distinct patient archetype:

  • Foundayo: the oral path. Captures the needle-averse market that injectable GLP-1s never reached and serves patients with weight loss targets in the 8-12% range.
  • Zepbound (tirzepatide): the dual-agonist injectable. Today's gold standard for 20%-range TBWL — broadly available, established prior authorization pathways, established post-marketing safety record.
  • Retatrutide: the triple-class injectable. Lilly's candidate for the bariatric-range pharmacotherapy tier — once approved, it will likely sit above Zepbound on formularies for high-BMI patients targeting ≥25% TBWL.

From a patient's standpoint, all three Lilly options offer LillyDirect logistics and the same underlying manufacturer track record. A patient who switches from Foundayo to Zepbound to retatrutide over time will likely do so under the same prescribing infrastructure — which makes these comparisons less about brand loyalty and more about clinical fit.

Practical takeaway

For most patients in 2026, the decision reduces to two clinical questions:

  • How much weight do you need to lose? If the target is 8-12% TBWL, Foundayo's oral path is fitted to the magnitude and avoids weekly injection. If the target is 20%+ TBWL (clearing comorbidity thresholds, approaching bariatric magnitudes), Foundayo is unlikely to deliver — discuss Zepbound today and retatrutide only if and when the FDA approves it (Lilly plans to submit its application in Q1 2027).
  • Can you live with a weekly injection? Patients who would not start an injectable at all should start Foundayo and reassess. Patients comfortable with weekly injection have access to a meaningfully larger efficacy ceiling today via Zepbound and (post-approval) via retatrutide.

Every individual prescribing decision should be made with a licensed clinician who can review the full FDA prescribing information for Foundayo, the patient's comorbidities, drug-drug interactions (particularly CYP3A4 inhibitors for Foundayo), and prior tolerability with the GLP-1 class. Retatrutide remains investigational and cannot be prescribed outside of clinical-trial enrollment in 2026.

Further reading

Frequently Asked Questions

Foundayo (orforglipron) was FDA-approved on April 1, 2026 — the first small-molecule (non-peptide) oral GLP-1 approved for chronic weight management. Retatrutide is not FDA-approved. The pivotal TRIUMPH-1 trial was published in the New England Journal of Medicine in September 2026 and TRIUMPH-2 in The Lancet in 2026; Lilly plans to submit a Biologics License Application to the FDA in Q1 2027. As of October 2026, only Foundayo can be prescribed.
Cross-trial, retatrutide produced roughly 2.2× the mean TBWL of Foundayo at maximum tested dose — −25.0% TBWL at 12 mg over 80 weeks in the published TRIUMPH-1 trial (NEJM, treatment-regimen estimand) vs about −11% at 17.2 mg over 72 weeks in ATTAIN-1 — a roughly 14 percentage-point absolute gap. (Lilly's press release reported −28.3% for retatrutide 12 mg, but that figure used the efficacy estimand, which counts only participants who stayed on treatment.) This is an indirect comparison; no head-to-head trial of retatrutide vs orforglipron exists. The magnitude gap should be treated as directional rather than precise. Discuss the comparison with a prescriber who can weight your individual BMI, comorbidities, and weight-loss targets.
Yes. Both retatrutide (investigational) and Foundayo (orforglipron, FDA-approved April 2026) are Eli Lilly molecules. This is a within-portfolio comparison, not a brand-vs-brand-competitor framing. Lilly's GLP-1 portfolio also includes Trulicity (dulaglutide, injectable monoagonist for T2D) and Mounjaro/Zepbound (tirzepatide, dual GIP+GLP-1 injectable). Each molecule targets a distinct patient archetype within Lilly's strategy.
Retatrutide activates three receptors simultaneously: GIP, GLP-1, and glucagon. Glucagon receptor activation increases hepatic energy expenditure, promotes lipolysis, and reduces hepatic steatosis — mechanisms that single-receptor GLP-1 agonists like Foundayo cannot access. Foundayo activates only the GLP-1 receptor. The mechanism asymmetry is also the magnitude asymmetry: more receptor activation drives larger weight loss but also amplifies the adverse-event signal, including a dysesthesia signal in TRIUMPH-1 far more frequent than in Foundayo's trials.
Foundayo is a once-daily oral tablet. It is a small-molecule non-peptide compound, so it survives gastric digestion and is absorbed without the strict empty-stomach plus 4-ounce water requirements of Rybelsus (oral semaglutide). It can be taken at any time of day, with or without food. Retatrutide in the TRIUMPH program is a once-weekly subcutaneous injection administered via a prefilled pen device. The route difference is the practical headline: needle-averse patients have an FDA-approved oral path with Foundayo today.
No, not legally. Retatrutide is not on the FDA 503A bulk-substance list, has no USP monograph, and is not a discontinued FDA-approved drug — so it does not qualify for legal 503A pharmacy compounding. Any product marketed as 'compounded retatrutide' in 2026 is not produced under the FDCA 503A framework and carries unverified identity, potency, and sterility risk. The only legal pre-approval access pathway is enrollment in an active retatrutide clinical trial. Foundayo is the FDA-approved oral GLP-1 option available today through standard pharmacies and the Foundayo Self Pay Pharmacy portal.
Cross-trial, retatrutide's AE burden is higher. TRIUMPH-1 nausea ran roughly 42% on retatrutide 12 mg vs roughly 5-10% discontinuation on Foundayo 17.2 mg in ATTAIN-1. Retatrutide also carries a dysesthesia signal (~12.5%) far more frequent than in Foundayo's trials (1% at 17.2 mg). Both classes share the standard GLP-1 boxed warning for thyroid C-cell tumor risk plus pancreatitis, gallbladder, and renal warnings. Foundayo also has a specific 9 mg dose cap with strong CYP3A4 inhibitors that the peptide GLP-1 class does not have.
Probably not — these molecules likely target different patient segments. Foundayo is the oral path for needle-averse patients and patients targeting 8-12% TBWL. Retatrutide, once approved, will likely be positioned for high-BMI patients targeting bariatric-range outcomes (≥25-30% TBWL). The decision will hinge on the patient's BMI, weight-loss target, tolerance for weekly injection, and history with the GLP-1 class. A patient who succeeds on Foundayo at 10% TBWL with full label adherence is unlikely to switch to a harsher-AE-profile injectable for marginal additional efficacy.
Not in 2026. Retatrutide is investigational and cannot be prescribed for clinical use outside of enrollment in an active clinical trial. Lilly plans to submit a Biologics License Application in Q1 2027, so commercial availability depends on the timing and outcome of FDA review. A prescriber can absolutely discuss your candidacy for clinical trial enrollment, your fit for Foundayo today, or whether Zepbound is a better near-term option while you wait for retatrutide's approval. Always discuss medication decisions with a licensed clinician who can review your full medical history and FDA prescribing information.

References

  1. 1.Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PMID: 37366315.
  2. 2.Wharton S, Aronne LJ, Garvey WT, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025. PMID: 40960239.
  3. 3.Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1 pivotal Phase 3 results, May 2026). PR Newswire (Eli Lilly Investor Release). 2026. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html
  4. 4.Giblin K, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: rationale and design of the TRIUMPH registrational program. Diabetes Obes Metab. 2026. PMID: 41090431.
  5. 5.Horn DB, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity (ATTAIN-2). Lancet. 2026. PMID: 41275875.
  6. 6.Aronne LJ, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3 ATTAIN-MAINTAIN trial. Nat Med. 2026. PMID: 42120723.
  7. 7.Pearson MJ, et al. Retatrutide and Lipid and Metabolite Profiles in Participants With Obesity With or Without Type 2 Diabetes. J Clin Endocrinol Metab. 2026. PMID: 42135195.
  8. 8.U.S. National Library of Medicine. TRIUMPH-1 (NCT05929066): A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight. ClinicalTrials.gov. 2024. https://clinicaltrials.gov/study/NCT05929066
  9. 9.U.S. National Library of Medicine / Eli Lilly. FOUNDAYO (orforglipron) tablets, for oral use — US Prescribing Information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62
  10. 10.Eli Lilly and Company. Foundayo (orforglipron) brand and Self Pay Pharmacy portal. Foundayo.com. 2026. https://www.foundayo.com
  11. 11.Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, et al.; TRIUMPH-1 Investigators. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026. PMID: 42814954.
  12. 12.Eli Lilly and Company. Lilly reports second-quarter 2026 financial results (Form 8-K exhibit). U.S. Securities and Exchange Commission. 2026. https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000077/q226lillysalesandearningsp.htm

Retatrutide vs Ozempic: T2D Phase 2 Cross-Trial Evidence (vs SUSTAIN-7)

Indirect T2D comparison: retatrutide 12 mg -2.02% HbA1c (phase 2) and -18.8% body weight at 80 wk (TRIUMPH-2, placebo-controlled) vs Ozempic 1.0 mg -1.8% HbA1c / -6.5 kg (SUSTAIN-7). Ozempic FDA-approved 2017; retatrutide investigational.

12 min read

Retatrutide vs tirzepatide — TRIUMPH-1 vs SURMOUNT-1 head-to-head evidence

Retatrutide -25.0% TBWL at 12 mg / 80 wk (TRIUMPH-1, NEJM 2026) vs tirzepatide -20.9% at 15 mg / 72 wk (SURMOUNT-1), about 4 points on a cross-trial basis. Nausea, a dysesthesia signal, and discontinuation run higher, and retatrutide is not FDA-approved.

11 min read

Retatrutide Side Effects: Comprehensive Phase 3 Evidence Review

TRIUMPH-1 pivotal phase 3 retatrutide adverse-event review: GI rates, a dysesthesia signal (12.5% vs 0.9% placebo) also seen with high-dose semaglutide, 11.3% discontinuation, and head-to-head AE comparison with Wegovy, Zepbound, and Foundayo.

15 min read

Foundayo (Orforglipron) Side Effects: Comprehensive Evidence Review

Comprehensive Foundayo (orforglipron) adverse-event review across the three pivotal trials: ATTAIN-1 in obesity, ATTAIN-2 in T2D, and ATTAIN-MAINTAIN switch-and-maintain. GI dominance, dose discontinuations, class warnings, and head-to-head AE comparison with Wegovy and Zepbound.

14 min read

Retatrutide Before and After: What TRIUMPH-1 Actually Showed

TRIUMPH-1 (n=2,339; NEJM 2026) reported -25.0% mean weight loss at 80 weeks on retatrutide 12 mg (intention-to-treat; Lilly's press release cited -28.3% on-treatment). Honest framing of transformation magnitude, dose-response, and real-world expectations.

12 min read

Orforglipron (Foundayo) Side Effects: Label Trial Rates

What the FDA Foundayo label and the ATTAIN-1 phase 3 trial actually report for orforglipron side effects — the GI rates, the boxed MTC warning, the pancreatitis and gallbladder signal, and how the oral pill compares to injectable Wegovy and Zepbound.

11 min read

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Read full review →

From $129/mo

starting dose

Get started →
8.3

Found

Medication-included compounded GLP-1 on 28-day cash plans, plus insurance help for brand-name GLP-1s

Read full review →

From $289/4 wks

billed per 4 weeks

Get started →
8.1

Oak

Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up

Read full review →

From $200/mo

starting dose

Get started →

About this analysis

Weight Loss Rankings is an independent editorial publication. Our provider dataset is verified directly against each provider's website and updated continuously. Read our full methodology →